{
  "id": 16188884,
  "title": "Abbott’s colorectal cancer test shows improved sensitivity",
  "url": "https://urgent.news/2026/10/23/abbotts-colorectal-cancer-test-shows-improved-sensitivity",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-23T13:20:35.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/abbotts-colorectal-cancer-test-shows-improved-sensitivity-93CH-4969611"
  },
  "original_language": "en",
  "account": "Abbott Laboratories showcased enhanced capabilities of its Oncodetect molecular residual disease test for colorectal cancer at the European Society for Medical Oncology Congress. The whole-genome sequencing-based test demonstrated 72.2% sensitivity for detecting colorectal cancer recurrence within two years post-surgery, a significant improvement over its whole-exome sequencing version with just 42.2% sensitivity. The Beta-CORRECT study analyzed blood samples from 279 primarily stage II and III colorectal cancer patients, taken one month after surgery. The test detects circulating tumor DNA in a single blood draw and has not been cleared or approved by the U.S. Food and Drug Administration.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}